Pfizer Inc.

NYSE:PFE  
40.01
-0.09 (-0.22%)
Products, Expansion

Pfizer Initiates Phase 1 Study In U.S. Of Novel Oral Antiviral Therapeutic Agent Against Sars-Cov-2

Published: 03/23/2021 15:15 GMT
Pfizer Inc. (PFE) - Pfizer Initiates Phase 1 Study in U.S. of Novel Oral Antiviral Therapeutic Agent Against Sars-cov-2.
Pfizer Says In-vitro Studies Conducted to Date Show Pf-07321332 is Potent Protease Inhibitor With Potent Anti-viral Activity Against Sars-cov-2.